Proteome Sciences plc Stock

Equities

PRM

GB0003104196

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. 11:35:28 2024-04-26 EDT 5-day change 1st Jan Change
4.15 GBX +18.23% Intraday chart for Proteome Sciences plc +25.76% -8.39%

Financials

Sales 2022 7.78M 9.72M 13.27M Sales 2023 5.03M 6.28M 8.58M Capitalization 13.37M 16.7M 22.81M
Net income 2022 1M 1.25M 1.71M Net income 2023 -2M -2.5M -3.41M EV / Sales 2022 2.35 x
Net Debt 2022 7.92M 9.89M 13.51M Net Debt 2023 11.45M 14.3M 19.53M EV / Sales 2023 4.94 x
P/E ratio 2022
8.14 x
P/E ratio 2023
-5.46 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 78.76%
More Fundamentals * Assessed data
Dynamic Chart
1 day+18.23%
1 week+25.76%
Current month+22.42%
1 month+25.76%
3 months-9.59%
6 months-34.39%
Current year-8.39%
More quotes
1 week
2.98
Extreme 2.98
4.64
1 month
2.65
Extreme 2.6504
4.64
Current year
2.65
Extreme 2.6504
5.75
1 year
2.65
Extreme 2.6504
8.79
3 years
2.65
Extreme 2.6504
10.00
5 years
2.25
Extreme 2.25
10.00
10 years
2.20
Extreme 2.2005
43.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 20-09-14
Director of Finance/CFO 48 22-08-31
Chairman 71 93-12-09
Members of the board TitleAgeSince
Chairman 71 93-12-09
Director/Board Member 69 14-06-30
Director/Board Member 72 17-07-31
More insiders
Date Price Change Volume
24-04-26 4.15 +18.23% 423,867
24-04-25 3.51 +0.29% 412
24-04-24 3.5 +7.69% 0
24-04-23 3.25 0.00% 0
24-04-22 3.25 -1.52% 500

Delayed Quote London S.E., April 26, 2024 at 11:35 am

More quotes
Proteome Sciences plc is a specialist provider of contract proteomics services. The services enable drug discovery, development, and biomarker identification and employ workflows for the optimum analysis of tissues, cells, and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic, and therapeutic applications. SysQuant and TMT MS2 are its unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using super-depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents, which are sold for multiplex quantitative proteomics.
More about the company